graphical user interface
Advertisement
03/31/2021

Lygos reaches commercial-scale cannabinoid production capabilities

Kicking off in April with the goal of producing more than 100 kg of cannabinoids, Lygos' production campaign will be the first of several the Berkeley, Calif.-based company carries out this year to meet customer demand. 
David Salazar
Managing Editor
David Salazar profile picture

Vertically integrated ingredients provider has launched a commercial-scale production campaign for its cannabinoid business, Lygos CBX. Kicking off in April with the goal of producing more than 100 kg of cannabinoids, the production campaign will be the first of several the Berkeley, Calif.-based company carries out this year to meet customer demand. 

“We have completed this important milestone on our way to providing high-quality, traceable, and natural cannabinoids at a scale relevant to the consumer-packaged goods sector,” said Eric Steen, CEO of Lygos. “Our depth of expertise in developing novel technology and proven ability to produce sustainable ingredients enables us to commercialize new products faster than ever before. Importantly, the modularity we have designed into our cannabinoid platform allows us to quickly adapt to the evolving market and react to the developing demand for our products, starting with CBG (cannabigerol) and CBC (cannabichromene) and extending to a broader range of cannabinoids.”

Lygos said the Lygos CBx production platform features quality control measures meant to help ensure that its products meet high-quality standards with each batch and production sites. The upcoming fermentations will yield CBG, CBC, CBD and CBDA, or cannabidiolic acid — all meant to support new and existing commercial relationships. As the year progresses, Lygos said it expects larger production campaigns. 

“Over the past year, Lygos developed and scaled the CBx technology at an incredibly rapid pace,” said Nick Ohler, chief technology officer of Lygos. “Despite the enormous challenges of COVID preventing travel and requiring an entirely remote process transfer to the new site, the scaleup has been smooth and almost entirely as expected, which speaks to the skill of our technical team and the robustness of our process.”

Lygos said it would continue to expand its cannabinoid product portfolio, and that it plans to launch a suite of cannabinoid-based consumer products within the year. It also is working to co-develop cannabinoid-based products with such companies as High Beauty, Open Book Extracts and MetaLabs.